



**SOLBEC**  
**PHARMACEUTICALS LTD**

**SUPPL**

**APPOINTMENT OF DIRECTOR**

**Summary**

- Mr. Russell Barnett appointed to the Board of Directors

**Perth, Australia. 24 July 2007:** The Company (ASX: SBP) is pleased to announce that it has appointed Mr. Russell Barnett as a Director of the Company.

Mr. Barnett has over 15 years experience in technology commercialization, innovation management, new venture creation and venture capital markets with a wide range of organizations throughout the Asia Pacific region. He is the Principal and founder of Australian Venture Consultants Pty Ltd, a management consulting practice providing expertise in these areas to universities, research funding agencies and other innovation intensive organizations. Mr. Barnett holds a number of other directorships including Chairman of Kirke Securities Limited and non-executive director of Rewire Therapies Limited.

Mr. Barnett's experience and range of contacts will be of considerable benefit to the Company particularly in areas of strategy and innovation.

- End -

**Further Information:**

<b>David Sparling</b> General Manager Tel: (08) 9446 7555 Mob: 0417 721 972 Email: <a href="mailto:david.sparling@solbec.com.au">david.sparling@solbec.com.au</a>	<b>Tony Kiernan</b> Chairman Tel: (08) 9446 7555 Mob: 0418 912 843 Email: <a href="mailto:tony.kiernan@solbec.com.au">tony.kiernan@solbec.com.au</a>
---	--

**About Solbec**

Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better therapies for debilitating conditions and life-threatening diseases. With the assistance of a \$2.26M Australian Government Commercial Ready grant the company is currently progressing its key project, Coramsine<sup>®</sup> for the treatment of advanced solid tumours. The two proprietary ingredients of Coramsine<sup>®</sup> were isolated from the fruit of the Devil's Apple (*Solanum linnaeanum*). They show activity against some cancers and cause potentially therapeutic changes to the immune system. In addition to human health, Coramsine<sup>®</sup> has potential application to animal health and diagnostics. Solbec's business strategy is to partner or out-license Coramsine<sup>®</sup> for the final stages of pre-commercial development and marketing.

[www.solbec.com.au](http://www.solbec.com.au)

**END**